More and more studies are showing beneficial effects of PEMF in areas like oncology and the benefits of TENS and PEMF therapy in these areas are no longer limited to pain control and management. PEMF in cancer therapy may be a reality in the near future. There are also studies that PEMF can help to overcome some drug resistance in cancer. To read, PEMF THERAPY FOR DRUG RESISTANT CANCER, click here.
A recent review published in Cancer Medicine investigates the use of PEMF in cancer therapy. It investigates PEMF therapy in vitro, in vivo and human clinical studies that have focused on PEMF in oncology and the study concludes that “studies show that PEMF therapy is safe and promising compared to other available cancer therapies. In the future, PEMFs could be used not only as primary therapy but also in combination with other common antineoplastic therapies.”
PEMF in Cancer Therapy - Cancer's included in the Review
Studies included in the review focused on breast cancer therapy, colon cancer, liver cancer and melanoma.
One of the studies on breast cancer cells found that treatment selectively caused MCF7 cells to commit suicide but did not affect MCF10 cells in other words it caused cancer cells to die but did not affect normal breast cells. Another study found that PEMF therapy in mice daily resulted in a 30% to 70% breast tumor reduction and PEMF therapy for 360 minutes daily suppressed tumor growth at week 4 of therapy.
In one of the clinical trials, PEMF therapy was offered to 28 patients with advanced cancer including breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, glioblastoma and HCC carcinoma. None of the patients reported any side effects and four patients reported stable disease including a patient with thyroid cancer with biopsy-proven lung metastases, a patient diagnosed with mesothelioma metastatic to the abdomen, a patient with non-small-cell lung cancer and a patient with pancreatic cancer with biopsy-proven liver metastases.
To read the review on PEMF in cancer therapy, click here.